Drug Combo Proves Powerful Against Lung Cancer Hauppauge NY

A two-drug combination treatment in Hauppauge proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Bradley David Cohen
(631) 581-4400
111 Carleton Ave
Islip Terrace, NY
Patricia Burns, MD
631-751-8305
2500 Nesconset Hwy Ste 90
Stony Brook, NY
Mark David Lipshutz, MD
631-666-6752
24 E Main St
Bay Shore, NY
William Man Chan Cheng, MD
516-921-1442
Syosset, NY
Hasan A Rizvi, MD
516-666-0262
180 E Main St
Bay Shore, NY
Emmanuel C Sygaco
(631) 422-4545
435 Montauk Hwy
West Islip, NY
Jiyeon Kim, MD
631-758-7575
285 Sills Rd Bldg 16
East Patchogue, NY
Birgis Akhund, MD
631-425-2285
180 E Pulaski Rd
Huntington Station, NY
Mitchell Kenneth Karten, MD
516-572-8722
2201 Hempstead Tpke
East Meadow, NY
Maria T Grosse Perdekamp, MD
Hsc T15 040,
Stony Brook, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Risks for Childhood Cancer Survivors Hauppauge NY
People who survived cancer as children face a high lifelong risk for developing another cancer, a new study has found. A study that appears online May 26 in the Journal of the National Cancer Institute went further than earlier studies by following people from birth through age 79. The researchers analyzed data on more than 47,000 people who had been diagnosed with cancer before the age of 20.
- Exercise for Breast Cancer Survival Hauppauge NY
- Side Effect Of Chemotherapy Drugs Hauppauge NY
- Fungal Infection Treatments Hauppauge NY
- Delayed Prostate Cancer Therapy Hauppauge NY
- Exercise for Prostate Cancer Hauppauge NY
- Hormone Therapy for Lung Cancer Hauppauge NY
- Hormone Therapy for Breast Cancer Hauppauge NY
- Genetic Clues for Skin Cancer Therapies Hauppauge NY